uniQure N.V. (NASDAQ:QURE – Free Report) – Investment analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of uniQure in a note issued to investors on Monday, June 29th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of ($0.78) for the quarter, up from their previous estimate of ($0.83). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for uniQure’s Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.38) EPS, Q1 2027 earnings at ($0.93) EPS, Q3 2027 earnings at ($0.85) EPS, Q4 2027 earnings at ($0.72) EPS, FY2027 earnings at ($3.46) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at $2.38 EPS and FY2030 earnings at $5.48 EPS.
uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%.
Check Out Our Latest Stock Analysis on uniQure
uniQure Price Performance
Shares of NASDAQ:QURE opened at $46.06 on Wednesday. uniQure has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a 50-day moving average price of $29.02 and a 200 day moving average price of $23.40. The company has a market cap of $2.91 billion, a P/E ratio of -13.24 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.
Insider Transactions at uniQure
In related news, CEO Matthew C. Kapusta sold 164,429 shares of uniQure stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the completion of the transaction, the chief executive officer directly owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the sale, the director owned 43,254 shares in the company, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 360,980 shares of company stock worth $14,617,140 over the last ninety days. 4.65% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On uniQure
A number of large investors have recently added to or reduced their stakes in QURE. Woodline Partners LP increased its holdings in uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of uniQure in the second quarter valued at about $497,000. Marshall Wace LLP grew its position in shares of uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after purchasing an additional 163,749 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of uniQure in the second quarter valued at approximately $540,000. Finally, Ameriprise Financial Inc. grew its position in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after purchasing an additional 212,218 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.
Key uniQure News
Here are the key news stories impacting uniQure this week:
- Positive Sentiment: HC Wainwright raised its earnings outlook across multiple periods for uniQure, including FY2026, FY2027, FY2028, FY2029 and FY2030, reflecting improving long-term profit expectations. uniQure analyst estimate update
- Positive Sentiment: The firm reiterated a Buy rating and a $80 price target, signaling analysts see meaningful upside from current levels. uniQure analyst rating update
- Neutral Sentiment: Insider Walid Abi-Saab sold 1,434 shares, a relatively small transaction that reduced his ownership by 0.85%, which may not be material but can still attract trader scrutiny. Insider sale alert
- Negative Sentiment: uniQure is still expected to remain loss-making in the near term, with consensus FY2026 EPS at -$3.65, so the business continues to rely on pipeline execution rather than current earnings strength.
About uniQure
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Read More
- Five stocks we like better than uniQure
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
